Skip to main content

Table 3 Response and number of [177Lu]Lu-DOTA-ZOL treatment cycles administered according to the extent of disease

From: [177Lu]Lu-DOTA-ZOL bone pain palliation in patients with skeletal metastases from various cancers: efficacy and safety results

Extent of skeletal metastases Number of patients (%) Response according to VAS assessment criteria (number of patients) Number of cycles administered Response according to global pain assessment criteria (number of patients) Number of cycles administered
< 6 2 (5%) CR-1 2C PR-2 1st patient-1C
PR-1 1C   2nd patient-2C
6–20 17 (42.5%) CR-5 4 patients-2C, 1 patient-1C CR-1 2C
PR-9 5 patients-2C, 4 patients-1C PR-11 8 patients-2C, 3 patients-1C
MR-1 2C MR-3 2 patients-1C, 1 patient-2C
NR-2 Both patients-1C NR-2 Both patients-1C
> 20 7 (17.5%) CR-2 2 patients, 2C CR-1 2C
PR-4 3 patients-2C, 1 patient-1C PR-4 3 patients-2C, 1 patient-1C
MR-0 0 MR-1 2C
NR-1 1C NR-1 1C
Superscan/diffuse 14 (35%) CR-3 All patients-2C CR-0
PR-6 5 patients-2C, 1 patient-1C PR-8 6 patients-2C, 2 patients-1C
MR-4 1 patient-2C, 3 patients-1C MR-5 3 patients-2C, 2 patients-1C
NR-1 1 patient 1C NR-1 1C
  1. VAS visual analogue score, CR complete response, PR partial response, MR minimal response, NR no response, C cycles